Dapirolizumab pegol

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameDapirolizumab pegol
Drug Alias Name培达利组单抗dapirolizumabum pegolum培戈-达匹利珠单抗Anti-CD40L-FabAnti-CD40L-Fab-PEG +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionCD40 ligand inhibitors
TargetsCD40 ligand
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBiogen IncUcb
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlBiogen IncUcb Trading (Shanghai) Co Ltd
Inactive CompaniesUcb Biopharma SprlUcb Pharma
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsAutoimmune DiseasesImmune System DiseasesConnective Tissue Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A